Researchers found a new way of predicting survival in malignant pleural mesothelioma patients. The prognostic model takes information from the health record to predict survival.
Mesothelioma is a rare form of cancer caused by exposure to asbestos. The new prognostic model can help doctors decide on the best treatment plan. This is important for newly-diagnosed patients. And it will have a big impact on their prognosis and quality of life.
Many factors can affect a malignant mesothelioma prognosis. Some relate to the patient’s overall health and disease stage or type. While others have to do with the type of treatment the patient undergoes.
Several prognostic models have been developed for mesothelioma. These all include information from the patient’s record. And all of them are trying to predict patient survival.
The European Organization for Research and Treatment of Cancer (EORTC) scoring is popular. Another is the Cancer and Leukemia Group B (CALBG) index. And the Glasgow Prognostic Score (mGPS) has been used to predict mesothelioma survival. Unfortunately, none of these models are perfect.
New Prognostic Model
Scientists at the Marmara University Faculty of Medicine in Istanbul have created a new model.
The team analyzed the outcomes of 53 mesothelioma patients between 2011 and 2020. They looked at which factors were most likely to impact patient outcomes and to what degree.
They focused on patients who received a tri-modality treatment plan. A combined tri-modality includes surgery, chemotherapy, and radiotherapy. This approach is often used in mesothelioma patients.
“Our aim was to provide a cheap, easily accessible, and reproducible prognostic index…,” says author Tugba Basoglu. “Our aim is to investigate a non-invasive and better predictor model for survival in daily practice.”
The model uses 5 different clinical factors in the equation. It included white blood cell (WBC) count, albumin, serum calcium level, LDH, and ALP levels.
The new prognostic model shows some early success. It was successful in predicting survival outcomes in most mesothelioma patients. The new model is a powerful tool for oncologists. And it offers hope to those newly-diagnosed with mesothelioma.
Basoglu, Tugba, Nazim Can Demircan, Tugce Kubra Gunes, Mehmet Umut Capar, Merve Cinar, Rukiye Arikan, Tugba Akin Telli, Ozlem Ercelep, Faysal Dane, and Perran Fulden Yumuk. “A Laboratory Prognostic Index Model for Predicting Survival in Patients with Malignant Pleural Mesothelioma.” (2022). https://www.ejmi.org/10.14744/ejmi.2022.38653/